RNA Formulation Videos

  1. The Scientific Underpinnings Of mRNA/LNPs 11/28/2022

    In this video, Russell Johnson, VP Formulation Research for RVAC Medicines, and Aalok Shah, Director of Formulation & Drug Delivery, Strand Therapeutics, share their thoughts on the scientific-research and CMC-related reasons that have made the lipid nanoparticle the “darling” of the delivery world for mRNA/RNA products today.

  2. Analytical Solutions To Help Accelerate Bioprocessing Success 11/1/2024

    Unlock the power of data-driven bioprocessing. Discover how advanced analytics can optimize your cell culture process, improve performance, and accelerate success.

  3. Nanoparticle Enabled Formulation And Drug Delivery Solutions

    Discover how revolutionary and environmentally sustainable nanoparticle technologies coupled with innovative formulation approaches can address drug solubility issues and add value for patients.

  4. Molecular And Colloidal Ionization Properties Of Lipid Nanoparticle mRNA Vaccines 4/13/2022

    Dr. Michael Buschmann, George Mason University, presents an overview of molecular and colloidal ionization properties of lipid nanoparticle mRNA vaccines.

  5. Role Of Membrane Chemistry And Filter Format In TFF 9/2/2026

    Compare hollow fiber and flat sheet TFF formats across three membrane chemistries, and see how filter selection can influence ambient-temperature UF/DF optimization, processing time, and quality.

  6. R&D & CMC Priorities For LNPs Beyond Cell-Specific Delivery 12/4/2024

    It goes without saying that achieving cell-specific delivery is the most often discussed challenge facing the RNA-LNP field near- and long-term. However, as these three LNP experts share in this Advancing RNA Live clip, they have a whole list of additional R&D and CMC priorities we must address/accomplish to improve RNA-LNPs’ efficacy in personalized and gene therapy approaches.

  7. What Innovations Could Help Us Overcome Preclinical Model Limitations For RNA-LNPs? 12/4/2024

    In this Advancing RNA Live clip, BioNTech’s Ben Muir and Hopewell Therapeutics’ Kate Zhang share their perspectives on the most exciting novel screening methods, innovative preclinical models, and next-gen technologies they hope can/will eventually help us bridge the translation gap between preclinical models and the clinic.

  8. RNA-LNP Manufacturing Technology Delivering Transformative Medicines 10/13/2022

    NxGen™ microfluidic technology enables controlled and precise assembly of high-quality, uniform LNPs, ensuring reproducible scale-up of RNA-LNPs while maximizing drug loading and particle quality.

  9. Defining A "Next-Gen" LNP 11/28/2022

    Russell Johnson, VP Formulation Research for RVAC Medicines, and Aalok Shah, Director of Formulation & Drug Delivery, Strand Therapeutics, share their expectations on which scientific advancements/characteristics will be most important for LNP-delivery of mRNA/RNA cargo in the future.

  10. Goldilocks & The 3…CQAs? Finding "Just Right" With LNP Optimization 12/4/2024

    Three LNP experts from Sanofi, Hopewell Therapeutics, and BioNTech collectively discuss how far we’ve come in understanding the structure of our LNPs while also shedding light on the variables that have the greatest potential of causing shifts in our products’ structure/function.